HEMGENIX - AN OVERVIEW

Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately extreme to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some individuals who are classified as owning moderate or reasonable condition might have a significa